ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting 76 enrolled ORIC Pharmaceuticals Janssen Research and Development LLC · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Timeline

Start: 2025-02-27
Primary completion: 2026-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ORIC-114	Small molecule	—	Oral
Background	Amivantamab	Monoclonal antibody	—	Subcutaneous

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Summary

Timeline

Drugs

Indications